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Abstract 
Parkinson’s disease (PD) remains a serious concern due to its effects on the quality of life of patients and its 
socioeconomic burden to society. Present day management of PD has limitations in both diagnosis and 
treatment. Nanotechnology may provide smart solutions to this problem. The present review highlights the 
recent advancements in the development of nanotechnology platforms for PD. The review focuses on the 
use of such platforms in diagnostics, treatments, deep brain stimulation, neurosurgery and other 
modalities of management and the role of nanotechnology in each of these fields. The review also sheds 
light on the translation of technologies from labs to clinics and the essential advantages as well as concerns 
that accompany the translation.  
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Introduction 
Parkinson’s disease (PD), in the present day, ranks second after Alzheimer’s disease among the most 
common neurodegenerative diseases and has characteristic motor and non-motor symptoms [1]. Globally, 
the prevalence of PD has been found to be close to 0.3 % of the total population and the crude incidence 
rate is 4.5–19 per 1,00,000 population per year [2,3]. The World Health Organization computed the 
disability-adjusted life years (DALYs) or  the number of years lost of healthy life, due to PD to be 1,617,000 
globally in 2005 and projected it to increase to 2,015,000 years by 2030 [3]. It would mean that more and 
more people would be leading lives with disabilities due to Parkinson’s disease. Besides, there is a huge 
cost that is incurred globally for the management of PD. In developed countries like the United States, the 
national economic burden of PD was more than USD 14.4 billion in 2010 (approximately USD 22,800 per 
patient) [4]. In developing countries like India, patients with PD were found to spend nearly 16 % to 41.7 % 
of the average Indian gross national income as direct costs in the treatment of PD [5]. Thus, PD is a 
universal disorder and in addition to the clinical features, the socioeconomic impact of PD is a cause of 
concern.  
The management of PD has several limitations at present. The clinical diagnosis of PD originates to the 
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acclaimed neurologists like Parkinson and Charcot who observed that the presence of two or three motor 
features including bradykinesia, rigidity and tremor was characteristic of Parkinson’s disease [6]. Two 
centuries later, the issue with the clinical diagnosis of Parkinson’s disease today is that it fails to 
differentiate it from the many other forms of parkinsonism [7]. Also, it requires expert clinicians for the 
evaluation of these subjective features of the disease. Thus, there is a need for better biomarkers that can 
provide for an objective assessment of the presence or absence of PD. Beyond the diagnosis, standard 
treatment modalities comprise of therapy using dopamine agonists and dopamine precursors to improve 
clinical symptoms associated with disease progression, patient’s care and quality of life. However, short 
half-lives, treatment intolerance together with side effects like levodopa (L-3,4-dihydroxyphenylalanine or 
L-DOPA) induced dyskinesias limit the long term treatment efficacy. Further, therapy is limited by the 
presence of the “blood-brain-barrier”. Thus, in the sphere of treatment for PD, there is a need to develop 
efficient therapies with minimal side-effects and increased bioavailability in the central nervous system. 
Nanotechnology, an emerging tool, has the potential to improve these circumstances by introducing 
novel carrier-based platforms that will target selective release of drug payload with on-demand and 
controlled release kinetics and increased reach via modulating or by-passing the blood-brain-barrier. The 
present review describes the use of nanotechnology-based platforms for diagnosis, drug delivery and other 
therapeutic approaches.  
Epidemiology of Parkinson’s Disease 
Prospective and well-designed population based studies reported that prevalence and incidence rates 
of PD were age-specific i.e. onset of disease is rare below 50 years of age whereas sharp rise (~1-1.5 %) is 
seen over 60 year of age resulting in prevalence less than 0.04 % below the age 40 years, which rises to 
19 % above the age of 80 years [2,8]. The prevalence of PD varies by gender (men are more prone to PD 
than female, possibly due to the neuroprotective effect of estrogens), race/ ethnicity (incidence rates were 
found to be highest among Hispanics>non-Hispanic>Whites>Asian>Blacks) [9]. Differences in 
environmental factors like occupational exposures (pesticides, heavy metals) and cigarette smoking; 
dietary factors (anti-oxidants like vitamin E, fatty acids mainly unsaturated fatty acids, dietary iron etc.), 
genetic factors like α-synuclein (PARK1), parkin (PARK2), genes involved in dopamine metabolism, 
homocysteine metabolism and polymorphism in mitochondrial DNA etc. are responsible for PD progression 
with variations in its prevalence and incidence [9].  
Etiology and Pathophysiological Hallmarks of Parkinson’s Disease 
For designing of successful diagnostic and therapeutic strategies against PD it is important to 
understand the etiology and pathophysiology behind development and progression of PD. PD is a chronic, 
progressive neurodegenerative disease characterized by impairment in motor and non-motor activities 
with symptoms like akinesia, tremor, muscle rigidity, postural instability, freezing of gait and depression, 
delirium, dementia, sleep disorders, autonomic symptoms (bradycardia, sialorrhea, sexual dysfunctions 
and dry eyes syndromes etc.) and other symptoms like olfactory disturbances, fatigue, weight changes etc. 
The classical pathophysiological hallmark of PD is the presence of Lewy bodies in the dopaminergic 
neurons that are left behind after degeneration of these neurons in substantia nigra pars compacta. This 
results in dopamine depletion in the striatum and basal ganglia nuclei due to innervations of dopamine 
neurons in two segments of globus pallidus i.e. external and internal parts of basal ganglia nuclei and also 
auxiliary to subthalamic nucleus and thalamus [10]. The etiological factors include toxins mainly MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) which produced MPP+ (1-methyl-4-phenylpyridinium), a 
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neuro-toxic precursor by monoamine oxidase-B (MAO-B) that further interferes in mitochondrial 
metabolism leading to free radical generation and subsequently causes dopaminergic neuron degeneration 
in the substantia nigra [11]. Various other toxins include TaClo (formed from interaction between sedative 
agents like chloral or organic solvents like trichloroethylene with endogenous tryptamine) were also 
reported to be toxic to dopaminergic neurons [12]. Other pathological hallmarks includes degeneration of 
non-dopaminergic neurons leading to depletion of nor-adrenaline, serotonin (depletion or hyperactivity of 
5-hydroxy tryptamine in the brain giving rise to symptoms such as depression and hallucinations), glutamic 
acid, gamma-amino butyric acid (GABA), neuropeptides like endorphins (enkephalins and dynorphins) and 
acetylcholine etc. [13-16].  
The pathophysiology of PD remains ambiguous, and is under continuous active investigations till date. 
Olanow and Tatton (1999) have reported that potential genes like glutathione peroxidase, superoxide 
dismutase-1, 2 and dopamine receptors (D2-4) etc. contribute to 5-10 %  familial PD with autosomal 
dominant or recessive inheritance [17]. The pathogenesis of PD includes oxidative stress in substantia nigra 
through production of reactive oxygen species (ROS) and hydrogen peroxide by extensive oxidative 
metabolism of dopamine.  Collectively, the increased turnover of dopamine, decreased glutathione levels 
and presence of reactive iron promotes generation of free radicals which may  be responsible of disease 
development and progression [17]. Previous studies reported oxidative damage to the DNA {elevated 
levels of 8-hydroxyguanine (8-OHG)}, in substantia nigra of PD patients due to free species like 
peroxynitrite, hydroxyl radicals etc. [18]. In 1990, Schapira and co-workers reported the role of increased 
mitochondrial dysfunction in PD patients and  association  with defects in mitochondrial complex-I of the 
respiratory chain leading to nigrostriatal neuronal degeneration through depletion of ATP synthesis [19]. 
Several studies demonstrated that different genes like α-synuclein, parkin and UCH-L1 (gene encoding 
ubiquitin carboxyl-terminal hydrolase L1) act concomitant with an increased mitochondrial dysfunction and 
oxidative damage in PD patients [20]. Song et al. (2004) reported a co-relation between α-synuclein and 
mitochondrial function, since α-synuclein transgenic mice were susceptible to neurotoxic effects induced 
by MPTP whereas, resistance was observed in α-synuclein knockout mice [20]. Sheng et al.  reported the 
up-regulation or mutation in α-synuclein leads to formation of abnormal and misfolded proteins  through 
series of events like oligomerization, fibrilization and aggregation within the nerve cells (formation of Lewy 
bodies) that responsible for mitochondrial dysfunction, impaired neuronal homeostasis and lead to 
subsequent neurodegeneration [21]. Several studies reported the role of genetic factors in pathogenesis of 
PD such as extensive generation of Lewy bodies one of the pathophysiological hallmarks associated with 
mutated α-synuclein causing early and late onset of PD with rapid disease progression whereas, mutated 
LRRK2 showed late onset of PD (at 80 years of age) with Lewy bodies formation, however dementia was 
not observed and also mutated ATP13A2 cause an atypical PD with dementia [22-24]. Another study 
demonstrated that activated macrophages and microglia responsible for secretion of different 
neurotrophic factors like brain derived neurotrophic factor (BDNF), and glial derived neurotrophic factor 
(GDNF) cause dopaminergic sprouting in nigrostriatal injury in PD patients [25].  
Paul and colleagues reported the significant role of ubiquitin–proteasome system (UPS) and autophagy 
(macroautophagy) pathways in lysosomal and proteasomal dysfunction,  another pathophysiological 
hallmark of PD [26]. Further studies reported the damage to UPS and lysosomal pathways (increased 
protein accumulation due to impaired unwanted protein clearance mechanism) through mutated genes 
like Parkin, LRRK2 causing neuronal toxic insult in PD [27]. 
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Impaired iron metabolism concomitant with different genetic (α-synuclein aggregation) and 
environmental (tobacco, cigarette smoking) factors was observed in pathogenesis of sporadic or familial PD 
[28]. Mitochondrial byproducts (peroxide and superoxide) can reactive with iron by generating most 
damaging hydroxyl radicals causing dopaminergic cell death in substantia nigra. These findings further 
supported by chronic MPTP treated mouse studies correlating iron levels with selective dopamine 
degeneration through lipofuscin aggregation and up-regulated α-synuclein [29]. PLA2G6 and ATP13A2 are 
two important genetic factors associated with increased neurodegeneration in brain. Iron accumulating in  
substantia nigra of PD patients have been reported by several studies however their precise mechanism of 
action is not yet clear [30,31]. Despite the significant progress in molecular and cellular studies, the 
detailed pathophysiology of PD is not yet clear.  
Present modalities of management and their limitations 
Current Techniques for Diagnosis of PD- Clinical Diagnosis and Imaging 
Accurate diagnosis plays an important role in the precise management of PD. Currently, diagnosis of PD 
is done on the basis of different clinical symptoms of parkinsonism like bradykinesia, tremor, postural 
imbalance, dementia, sleep disorders, sialorrhea, dry eyes syndromes and olfactory disturbances, fatigue, 
weight changes [32]. Presence of Lewy bodies in substantia nigra, hypothalamus, basal nuclei, and cranial 
motor nerve and its nuclei etc. is an important biomarker for PD diagnosis. Different genetic and imaging 
testing were carried out for diagnosis of PD. Identification of genetic mutations revealed that α-synuclein, 
NURR1, LRRK2 and UCH-L1 are responsible for autosomal-dominant inheritance whereas,  DJ1, Parkin and 
PINK1 are responsible for autosomal-recessive inheritance [32]. The cranial CT scan, MRI and PET (fluorine-
18 labeled DOPA) imaging, SPECT (single photon-emission computed tomography) and transcranial 
ultrasound imaging etc. are valuable techniques for differentiation and diagnosis of PD from other 
neurodegenerative disorders. For instance, SPECT tracer used for presynaptic dopamine transporter 
imaging like FP-CIT (N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane binds to the 
dopamine transporters (DAT) protein. Thus, integrity of nigrostriatal dopaminergic transporter can be used 
as a diagnostic marker for detection of early PD progression [33]. However, accessibility and cost of these 
techniques restrict their usefulness and application in diagnosis of PD. 
Pharmacotherapy and Management of Parkinson’s Disease 
Currently different therapies are available for treatment of motor and non-motor complications 
associated with PD. Pharmacotherapy of PD includes treatment with drugs like L-DOPA, dopamine receptor 
agonist, catechol-O-methyltransferase (COMT) inhibitors, antagonists of MAO-B and glutamate and 
amantadine etc. L-DOPA is most widely used therapy for treatment of PD because it easily crosses BBB and 
is converted into dopamine in presence of an enzyme DOPA-decarboxylase. However, long term treatment 
with L-DOPA results in various side effects like dyskinesia (involuntary and non-rhythmic choreic or choreo-
dystonic movements), alterations in on-off periods giving rise to motor fluctuations, nausea and vomiting 
[34]. Therefore, in clinical practice L-DOPA is co-administered with Carbidopa (DOPA-decarboxylase 
inhibitor) in which Carbidopa itself does not cross BBB but reduces conversion of L-DOPA to dopamine in 
peripheral nervous system and thereby increase its delivery to the brain [35]. COMT inhibitors 
(entacapone) are ineffective when administered alone, therefore they are  administered as  adjuvants with 
Levodopa and Carbidopa in PD patients to avoid end-off-dose alterations [36]. Early PD symptoms are 
treated with MAO-B inhibitors like selegiline or rasagiline. Recently, Schapira et al. (2013) reported the dual 
action of safinamide (selective and reversible MAO-B inhibitors that decrease glutamate release via 
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blocking voltage depended sodium channels) by preventing dyskinesia and motor fluctuations in early PD 
patients [37]. Further randomized and double blind phase II/III studies demonstrated the anti-parkinson 
efficacy of safinamide therapy in PD patients [38]. Dopamine (post-synaptic D2 receptors) agonists such as 
non-ergot derivatives (pramipexole, ropinirole and rotigotine) are also used in early PD patients (above age 
of 60 years). However, treatment with dopamine agonists is not free from side effects like confusion, 
hallucinations and psychosis etc. Recent studies described the role of Adenosine A2A receptor antagonists 
in treatment of PD through increased activation of dopamine (D2) receptors via inhibiting adenosine 
receptors in striatum and basal ganglia nuclei. For instance, adenosine A2A receptor antagonist 
(Istradefylline) an adjuvant with levodopa has significant potential to prevent levodopa induced off-time 
fluctuation and dyskinesia [39]. Glutamate, an excitatory neurotransmitter in brain, has a significant role in 
pathogenesis of PD; hence glutamate receptors (subtypes of glutamate receptors like N-methyl-D-aspartic 
acid (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) antagonists can be co-
administered with levodopa to alleviate dyskinesia and other motor symptoms. Recent clinical trials with 
AFQ056 (mGluR5 i.e. metabotropic glutamic receptor antagonist) demonstrated an anti-dyskinetic therapy 
with improvement in motor symptoms. However, glutamate receptor antagonists are associated with 
various side effects like fatigue, and gastrointestinal symptoms [40].  
Different antioxidants (Coenzyme Q10 and N-acetyl-cysteine) that scavenge reactive oxygen species 
may have potential in preventing oxidative stress and dopaminergic neuronal degeneration in the 
nigrostriatal pathway in PD [41]. Neuroprotective therapies include use of various neurotropic factors like 
GDNF may induce dopamine differentiation/regeneration, and improved motor functions [42]. However, 
unsatisfactory pre-clinical outcomes were observed since neurotropic factors have limited BBB 
permeability when administered systemically. Their direct administration through intraputaminal 
implantation into basal ganglia has been reported in a randomized clinical trial by Lang and colleagues [43]. 
However, patient-friendly and non-invasive approaches need to be developed for effective and safe 
neurotropic therapy in PD in the future [43].  
Neuronal signaling in the central nervous system occurs through a combination of different electrical 
and chemical signals which maintain the homeostasis by precise regulation of ionic composition across the 
system. However, this neuronal regulation is defined by presence of barrier layers across the system. There 
are three different types of barriers at the interface of blood and the central nervous system i.e. blood-
brain-barrier (BBB), blood-cerebrospinal fluid-barrier (BCSFB) and the arachnoids barrier. The BBB is widely 
studied as it is the major limiting factor for exchange between blood and brain. BBB with average surface 
area of about 200cm2 g-1 is formed by the brain microvascular capillary endothelial cells (BMVEC) 
comprising tight junctions (TJs) formed by proteins like occludins, claudins, zonula occludens etc., adherent 
junctions (AJ) proteins like catenins, cadherins; and junctional adhesion molecules [44], astrocytes (BBB 
endothelium enclosing glial cells), basement membrane  and pericytes (undifferentiated connective tissue 
cells that promote proliferation, migration and differentiation of endothelial cells). Together these 
structural components play a dynamic role in maintaining brain homeostasis, barrier function and integrity 
of the BBB [45]. Tight junctions maintain high transepithelial electrical resistance (1500-2000Ω cm2 over 
other peripheral microvessels) which shields the brain from different neurotoxins. The BMVEC lacks 
fenestrations and is reported to have a higher mitochondrial load as compared to other endothelial cells 
consequently playing an important role in the active transport of nutrients to the brain [46]. Different 
efflux transporters (P-glycoprotein, multidrug resistance associated proteins), enzymes (γ-glutamyl 
transpeptidase, alkaline phosphatase) and receptors (low density lipoproteins receptor, epidermal growth 
factor receptor) are expressed on either luminal or abluminal membrane surfaces of BBB to prevent 
R. Banerjee et al.  ADMET & DMPK 3(3) (2015) 155-181 
160  
transport of substances across the barrier [47,48]. The high electrical resistance of tight junctions restricts 
the entry of macromolecules whereas ions and other polar compounds can only access the BBB via 
paracellular diffusion.  There are various specific and selective pathways for transport of different nutrient 
molecules across BBB (like solute carriers, transporters for glucose, amino acids etc. However, presence of 
efflux transporters like P-gp and tight junctions within the BBB are the additional challenges for effective 
drug delivery to the CNS [49,50].  
Standard pharmacotherapy for PD has a poor therapeutic efficacy, with only a symptomatic relief i.e. 
they do not modify or identify the progress or root cause of the disease and show treatment failure often 
associated with various side effects. The limitations of current therapeutic modalities, as outlined in Fig. 1 
need to be addressed for the appropriate treatment of PD. 
 
Figure 1. Limitations in the treatment of Parkinson’s disease 
Neurostimulation by Surgical Approaches 
Different surgical approaches have been under clinical practices for the management of PD.  Deep brain 
stimulation is one of the surgical approaches that involve implantation of CT/MRI guided electrodes in the 
subthalamic nucleus or in the globus pallidus. The impulse generator creates electrical stimulation affecting 
the firing pattern of neurons in the implanted area along with the release of neurotransmitters glutamate 
and adenosine and improves the motor symptoms in PD with neurogenesis in addition to causing an 
increased blood circulation in the  stimulated regions [51]. Several studies have reported that deep brain 
stimulation as an adjuvant with pharmacotherapy showed significant improvements in patient daily 
activities and quality of life by reducing motor disability, levodopa induced motor fluctuations [52]. 
However, it is often associated with many adverse effects like intracranial hemorrhage, cognitive 
impairment, anxiety, infection and post-operative seizures. [53,54]. Thalamotomy, is an invasive approach 
performed using a probe in region contralateral to the tremor and lesion in severe PD cases. Recently 
transcranial MRI guided focus ultrasound technology was use to perform thalamotomy which significantly 
reduced tremor, postural disability and improved the quality of life over a period of one year post-
treatment. However, side effects include cognitive impairment, paresthesia of tongue and figure, headache 
and nausea  [55]. Gamma knife (GK) is another non-invasive surgical procedure where the emitted gamma 
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radiations intersect within the target brain region within 15-30min under anesthesia and led to a significant 
improvement in tremor and daily activities after several months of treatment. However, GK procedure 
suffers from lack of target region accuracy hence demands guided assist for more precise neurostimulation 
against PD [56].  
Nanotechnology as a viable alternative 
Nanotechnology and nanoscience are the interdisciplinary areas involving the development of 
nanosized materials. The foundations of these areas and the concept of miniaturization involved were 
introduced by Richard Feynman half a century ago in his renowned talk titled: “There's plenty of room at 
the bottom.” [58]. Principally, nanoscience is directed toward manipulation of materials at atomic or sub-
atomic levels whose properties differ significantly from those of bulk matter whereas nanotechnology aims 
to exploit such manipulated materials for designing, characterizing, and production of improved structure, 
devices and systems with controlled size and shape (1-100 nm) for various applications [57]. 
Nanotechnology has found numerous applications in biomedical sciences referred to as nanomedicine. For 
the purposes of nanomedicine, the definition of a nanomaterial is not restricted to those below 100 nm in 
size but extend to various submicron sized materials. The key aspect is to exploit the size dependant 
change in properties of submicron sized materials that can be exploited for altered cellular responses. 
Nanostructures have been applied for diagnosis of diseases, imaging, as devices, for tissue regeneration as 
well as for drug delivery and therapeutics. Nanotechnology which involves the manipulation of various 
systems at the nanoscale can have potential in the management of Parkinson’s disease. A few advantages 
of nanotechnology platforms in PD are enlisted below:  
1. Nanotechnology can help in the development of sensors that are able to sense various 
biomarkers at low concentrations in the presence of other analytes and help in the 
development of affordable diagnostic devices. 
2. Nanotechnology-based drug delivery platforms play an important role to achieve better 
therapeutic efficacy and enhance bioavailability across BBB for the treatment of CNS disorders. 
The different platforms like active targeting using receptor mediated endo- or transcytosis, 
stimuli responsive nano-carriers and macrophage mediated passive targeting etc. are few of the 
approaches that can improve the treatment of PD. 
3. Nanotechnology can also improve neural prosthetic devices for deep brain stimulation with 
better contact with the brain. 
4. Nanotechnology can also help improve precision in neurosurgery through nano-level precision 
of Laser axotomies. 
5. Lastly, nanotechnology may be employed to develop platforms for effective stem cell therapy 
through various tissue engineering approaches. 
The role of nanotechnology in the development of smart platforms for the diagnosis and treatment in 
PD are discussed in the subsequent parts of the review.  
Nanotechnology-based platforms for diagnosis 
A brief outline of the technologies developed for the diagnosis of PD is shown in Figure 2. 
Nanotechnology is thus being infused into the in vitro diagnostics, novel biomarker identification and 
bioimaging modalities for the diagnosis of PD.  
R. Banerjee et al.  ADMET & DMPK 3(3) (2015) 155-181 
162  
 
Figure 2. Use of Nanotechnology in diagnosis of Parkinson’s Disease 
Parkinson’s disease faces the yet unmet need for development of well-established and validated 
biomarkers [58]. Hence, most of the present day end-points in the assessment of patient response in the 
clinics as well as in large clinical trials depend on subjective measures of patient response and scores 
obtained using scales like the Unified Parkinson's Disease Rating Scale [58].  As an improvement of the 
classical clinical features, these scales that included features like response to levodopa treatment along 
with motor evaluation were developed to improve accuracy of a clinical diagnosis [7]. However these 
scales still needed an expert clinician. In PD specifically, the clinical characters can be substantially masked 
due to compensatory mechanisms for many years and it is during this long prodromal period that there is 
further progression of Parkinson’s disease. [7]. Hence, a framework needs to be developed for 
incorporating clinical knowledge, pathology, genetics and molecular mechanisms along with objective tests 
for defining the criteria for the diagnosis of Parkinson’s disease [7]. This has led to effort like the 
Parkinson’s Progression Markers Initiative (PPMI) funded by the  Michael J. Fox Foundation as an effort to 
meet the unmet need of finding suitable biomarkers. 
Various platforms to detect and quantify these biomarkers, PD-associated pathologies, imaging 
modalities and clinical abnormalities are being considered in the diagnosis of Parkinson’s disease. A variety 
of nanoparticles manufactured from zinc oxide, carbon nanotubes, fullerenes etc. are described here which 
have the potential to be used in the diagnosis of PD. 
Detection of biomarkers 
The PPMI study is performing clinical tests on blood, urine and CSF samples; performing neuroimaging 
to identify better markers of the earlier and accurate diagnosis of PD and its progression [59]. The 
quantification of dopamine has been extensively used and has traditionally been estimated using 
spectrophotometry and chromatography.  
Nanotechnology platforms for detection of dopamine: There are a number of nanotechnology-based 
approaches that simultaneously detect dopamine with other biomarkers. Tashkhourian et al. developed a 
modified carbon-paste electrode for simultaneous quantification of dopamine and ascorbic acid [60]. The 
electrodes were modified to incorporate silver nanoparticles and carbon nanotubes, which led to more 
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efficient  electrochemical catalysis with high selectivity and sensitivity and a detection limit in micromolars 
for both the compounds [60]. In another study by Yue and colleagues, zinc oxide (ZnO) nanowire arrays 
(each nanowire being sub-100 nm in diameter and a couple of microns in height) were prepared upon a 
three dimensional foam made of graphene and the assembly could selectively detect dopamine along with 
urate and ascorbate by a method called differential pulse voltammetry. The addition of nanowires lead to 
high electrical conductivity and enhancement of sensitivity of electrochemical biosensors leading to 
reduction in the detection limit to 1 nanomolar for dopamine and uric acid in the serum of PD patients 
[61]. The field testing of this array lead to the interesting finding of a reduced UA level in 7 PD patients than 
in healthy individuals which can make uric acid a potential biomarker in the diagnosis of PD [61]. In yet 
another modification, Kurzatkowska et al. developed ion-channel mimetic self-assembled monolayers of 
macrocyclic polyamines deposited onto gold electrodes for electrochemical determination of dopamine 
[62]. The corrole molecules covalently attached on the surface of gold electrodes was an example of 
biomimicry of ligand-gated ion channels making the electrode surface semi-permeable to a redox marker. 
Upon addition of dopamine, a corrole-dopamine complex is formed on the monolayer leading to the 
recording of a positive charge on the electrode [62]. This allowed the detection limits to go down to the 
picomolar range [62]. Thus, the detection of dopamine can be made more sensitive and the detection 
limits can be reduced by orders of magnitude with the incorporation of nanotechnology-based smart 
platforms.  
Mitochondrial dysfunction: As another example, PD has been associated with mitochondrial dysfunction 
and  the inhibition of complex I comprising of NADH:ubiquinone oxidoreductase has been  implicated in the 
demise of dopaminergic neurons [19]. Ma et al. developed ubiquinone-quantum dot (CdSe/ZnS) 
bioconjugates in which complex I and NADH could modulate the emission from the nanocomplexes by 
simulating the electron-transfer system part of the mitochondrial respiratory chain [63]. The authors 
showed that the bioconjugates could be used to monitor changes in fluorescence to trace complex I levels 
in human neuroblastoma SH-SY5Y cells [63]. Though in the proof of concept stage, this technique has the 
potential to serve as an in vitro biosensor for the early detection of PD and in monitoring disease 
progression.  
α-synuclein detection: As described earlier, α-Synuclein is a very important neuronal protein associated 
with PD and present day strategies for its quantitative detection include sophisticated, time-consuming 
instruments including NMR spectroscopy, fluorescence measurements, western blotting and size-exclusion 
chromatography [64]. An et al. developed highly ordered microfabricated arrays using gold-doped 
TiO2 nanotubes for photoelectrochemical detection of α-Synuclein [64]. The arrays were effective 
platforms for the immobilization of primary antibodies while retaining their stability and α-Synuclein 
binding [64]. Then, the attachment of secondary antibody and gold nanoparticle-conjugated glucose 
oxidase, allowed excellent sensitivity by signal amplification. Glucose oxidase catalyzed the conversion of 
glucose into gluconic acid and hydrogen peroxide. Upon irradiating the other side of the titanium foil, the 
holes that were formed within the valence band of the nanotubes could be scavenged by the peroxide 
leading to a photocurrent proportional to  concentrations of α-Synuclein with a detection concentration in 
the range of pg/ml [64].  
Other novel concepts: There are a few other novel diagnostic concepts that are emerging. The use of 
breath tests to diagnose neurodegenerative disorders is one such advancement. A number of volatile 
organic compounds like styrene, butylated hydroxytoluene and hexadecane have been found in the breath 
of PD patients [65]. As an example of the use of nanotechnology in the sensing of such novel compounds, 
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organically functionalized nanoparticles like carbon nanotubes and gold nanoparticles were used by Tisch 
and co-workers [66]. The sensors were effective in distinguishing the breath prints of PD from healthy 
states with an accuracy of 78 % [66]. Similarly, the technology could identify Alzheimer’s disease and 
differentiate it from PD. 
Improved imaging technologies  
Imaging in PD is dependent on a number of sophisticated techniques like cranial CT, MRI, PET and SPECT 
which are mostly available at advanced healthcare centres and are expensive. A number of experimental 
approaches are being developed and have potential for the imaging and earlier diagnosis of PD. A few of 
these have been elaborated below.   
Iron metabolism: Homeostasis of various metal ions which are found to be altered characterize 
neurodegeneration in PD. Ortega and colleagues used this for chemical nano-imaging in vitro using 
synchrotron X-ray fluorescence nanoprobe (88 nm beam) which allowed detection of 10−18 g of iron within 
cellular structures around 100 nm diameter [67]. Results suggested that PD showed elevation of iron  in 
the substantia nigra pars compacta, with loss of tyrosine hydroxylase activity that may lead to reduced 
iron-dopamine binding making the dopaminergic neurons more prone to iron toxicity [67]. Thus, nano-
imaging forms an important part in the detection of newer pathways for neurodegeneration in PD. 
Theranostics:  GDNF can be delivered as a neuroprotective agent using microbubbles which are 
ultrasound responsive [68]. The use of such particles in simultaneous imaging and therapy can give rise to a 
theranostic approach in the management of Parkinson’s disease. Similar therapies have been developed 
for the treatment of cancers [69] and is very promising. A similar approach is the development of 
magnetic-field responsive nanoparticles that are capable of crossing anatomical barriers like the BBB and 
respond to an external magnetic field by releasing the encapsulated therapeutic payloads [70]. The field of 
theranostics is promising and yet to be well explored in the treatment of Parkinson’s disease. 
Detection of cell loss: In 1999, Damier et al. described a protocol based on immunostaining a protein 
existing in afferent striatonigral fibers called calbindin D28K [71]. Using this technique in post-mortem 
specimens,  researchers could delineate 60% of all neurons containing dopamine present in the substantia 
nigra pars compacta inside the zone that has high calbindin (nigral matrix), and the remaining 40% was 
found to exist, packed together as the zones poor in calbindin (nigrosomes) in the form of invaginated 
pockets within the nigral matrix [71]. The group identified a mean reduction of more than half of the total 
dopamine-containing neurons in PD as compared to controls [71]. Besides, the substantia nigra pars 
compacta showed that the degree of loss of dopamine-containing neurons correlated with the duration of 
disease [71].  Thus, the pattern of cell loss in PD was found using this experimental tool. Further 
advancements in the imaging of cells using quantum dots and gold nanoparticles can advance this imaging 
modality to track PD progression.  
Monitoring clinical abnormalities  
One of the interesting applications in the diagnosis of PD is the detection of clinical abnormalities. 
Arrays of stretchable strain sensors based on silicon nanomembranes that conform well to the skin have 
been proposed as wearable devices for detection of clinical abnormalities [72]. Nanofabrication allows the 
manufacture of such sensors coupled with added features like presence of ultrathin serpentine 
interconnects to improve the precision of diagnosis [72]. Exposure to tension and compression on a human 
wrist are used for detection of frequency of tremors and can be of use in the continuous monitoring of PD. 
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Other interesting clinical abnormalities including change in handwriting have also been explored for the 
diagnosis of PD [73].  
Nanotechnology platforms for drug delivery 
Active targeting by Trojan horse approach 
Nanotechnology based active targeting plays a crucial role in directing the neurotherapeutics at the 
target site through specific pathways. Nanoparticles are surface functionalized/modified with specific 
ligands like peptides (insulin, insulin like growth factor), antibodies or antigens for receptors/transporters 
that are expressed on BBB therefore, facilitating enhanced bioavailability through receptor mediated 
endocytosis into the brain. The peptidomimetic antibodies decorated on nanoparticles can be used as 
molecular Trojan horses to ferry large molecules like drugs and genes across the BBB [74,75]. Previous 
studies showed expression of different receptors mainly low-density lipoprotein (LDL) and low density 
lipoprotein related protein-1 and 2 (LRP-1,2) transferrin, P-gp efflux transporter on BBB [76]. The receptor 
mediated endocytosis involves ligand-receptor interaction resulting in endocytosis at the luminal side of 
BBB followed by translocation through the endothelial cytoplasm to the abluminal side and finally 
exocytosis allowing release of payload at the target site  [77]. The payloads may be in the form of a drug or 
a gene. Gene therapy is becoming a popular approach to treat PD with some drawbacks in currently 
available therapies like poor permeability of the gene vector across the BBB after intravenous 
administration which limits the therapeutic efficacy. Local intracerebral administration of the gene vector 
at the target site is often limited by lack of patient compliance due to high invasiveness and repetitive 
injection schedule. Schlachetzki and colleagues discussed trans-vascular delivery, a novel approach for 
gene therapy to the brain using targeted nano-carriers [74]. This approach can be of two types- the more 
invasive one involves BBB disruption, using the intracarotid infusion of vasoactive compounds or 
hyperosmolar solutions and the less invasive one involves the targeting of certain endogenous transport 
systems within the BBB. As an example of the latter, Zhang et al. delivered tyrosine hydroxylase gene to 
the brain using a PEGylated immunoliposome system with a targeting moiety in the form of a murine 
monoclonal antibody (MAb) to the rat transferrin receptor [78]. Receptors like transferrin play an 
important role in transporting iron to the brain through receptor mediated endocytosis. The technology 
functions as a Trojan horse to ferry the gene across the BBB and demonstrated reversible normalization of 
tyrosine hydroxylase (TH) activity in the striatum along with favorable behavioral effects in experimental 
models of parkinsonism in rats [78]. Carroll and colleagues (2010) have reported the transferrin receptor 
antibody (OX26) conjugated PLGA nanoparticles loaded with antioxidant has significant potential against 
oxidative stress induced neurodegenerative diseases [79]. The in vitro study showed higher cellular uptake 
and decreased cell viability of RG2 rat glioma cells with targeted nanoparticles as compared to non-
targeted nanoparticles through receptor mediated endocytosis. These findings suggest the potential of 
transferrin receptor in the treatment of other neurodegenerative diseases mediating the transport of drug 
across BBB [79].   
Lactoferrin is a cationic iron binding glycoprotein from one of the transferrin receptor family. Previous 
studies on lactoferrin receptors reported that their expression on BBB facilitates the transport of 
lactoferrin to the brain [80]. Ji and colleagues in 2006 have demonstrated the greater brain uptake of 
lactotransferrin than that of transferrin and OX26 (an anti-transferrin receptor antibody) through 
endocytosis mediated by receptors in an in vitro BBB study.  [81].Using this concept, Hu et al. in 2009 
demonstrated the improved brain targeting potential of lactoferrin conjugated PLGA nanoparticles as 
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compared to  unmodified nanoparticles [81]. Here lactoferrin acts as the ferrying moiety across the BBB to 
allow the Trojan horse- like delivery of payloads [81]. This finding showed higher brain uptake (3-fold) of 
lactoferrin modified nanoparticles in mice over non-modified nanoparticles [81]. Interestingly, in 2011, Hu 
et al.; further demonstrated  the successful brain delivery of Urocortin (corticotrophin releasing hormone 
related peptide) loaded lactoferrin conjugated polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) 
nanoparticles [82]. In vivo pharmacokinetic study of lactoferrin conjugated nanoparticles showed 2.49-
times increase in AUC than that of non-conjugated nanoparticles in 24h. The in vitro cellular study on 
immortalized mouse brain endothelial cell line (b.End3) revealed that the uptake of conjugated 
nanoparticles occurred through clathrin mediated endocytosis with minimal adverse effect on cell viability 
[82]. Further the conjugated nanoparticles showed significant reduction of striatum lesions in 6-OHDA (6-
Hydroxy dopamine) induced rat PD model. Together these findings revealed that lactoferrin is a promising 
targeting ligand to enhance targeting and accumulation of active to brain and lactoferrin decorated 
nanoparticles can help to deliver drugs more effectively in PD. Huang et al; (2010) demonstrated long 
term, non-invasive targeted gene therapy in rotenone induced chronic PD model using lactoferrin 
functionalized nanoparticles encapsulated with human glial cell line derived neurotrophic factor gene 
(hGDNF). The study revealed that intravenously administered lactoferrin decorated nanoparticles showed 
successful gene delivery to the brain through higher and long lasting GDNF expression in brain in 
experimental animals than that of single injection [83].   
The LRP-1 and 2 receptors interact with various other molecules like apolipoprotein-E (apoE) in addition 
to lactoferrin and melanotransferrin which have been widely studied for targeting against PD. Wanger et 
al. in 2012 have reported the potential of low density lipoprotein receptor related protein (LRP-2) for 
specific and effective apolipoprotein mediated nanoparticulate transport and uptake by brain capillary 
endothelial cells [84].  
A brief representation of the fate of actively targeted nanoparticles is provided in Figure 3. 
 
 
Figure 3. Use of targeted nanoparticles for active targeting in drug delivery for Parkinson’s Disease 
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Routes of administration to enhance drug delivery across BBB 
The presence of the BBB, limits the permeability of therapeutic agents to reach target sites in the CNS, 
resulting in insufficient bioavailability as well as poor treatment outcomes against neurodegenerative 
disorders. Several attempts have been made for effective and safe delivery of active into the CNS. Local 
drug delivery strategies include intrathecal, intraparenchymal and intracerebral injections directly at the 
target site for transporting the therapeutic active to the CNS. Direct drug delivery systems have potential 
to circumvent the BBB. Pillay et al.(2009) studied the binary cross-linked alginate scaffold embedded 
polymeric  (cellulose acetate phthalate) nanoparticles loaded with dopamine which after intracranial 
implantation showed enhanced and sustained dopamine delivery within CSF in Sprague–Dawley rat model 
with reduced peripheral side effects as compared to orally administered L-DOPA [85]. Worly et al. (2008) 
developed acrylated 3′-sialyllactose (bioactive epitope recognized by various growth factor receptors like 
EGFR) embedded within poly[N-(2-hydroxypropyl methacrylamide)] (pHPMA) hydrogels for intracranial 
implantation [86]. On intracranial implantation in 6-OHDA PD model, the hydrogel served as a three 
dimensional substrate promoting neuronal tissue remodeling and angiogenesis with high affinity for 
receptors [86]. These finding demonstrated that polymeric nanoparticulate hydrogels can act as effective 
carriers for local delivery of drugs in PD.  Nevertheless, these techniques are limited due to their invasive 
nature [77,87].  
Recently, intranasal routes through olfactory or trigeminal pathways have been explored for 
transporting actives to the brain. Intranasal administration has the potential to circumvent the BBB via 
intracellular or extracellular pathways. The intracellular pathways include endocytosis (adsorptive or 
receptor mediated) into olfactory sensory neurons followed by intraneuronal transport (transcytosis) into 
trigeminal nerves whereas, extracellular pathways include paracellular diffusion to the lamina propria 
through perineural or perivascular channels [88,89]. Intranasal administrations offer benefits like rapid 
onset of action and reduced systemic toxicities for delivering the therapeutics to the brain. However, 
mucocilliary clearance limits the residence time when drug solutions are delivered intranasally.  [90].  
Recently, Wen et al. (2011)  demonstrated that intranasal administration showed improved therapeutic 
efficacy of urocortin (corticotrophin releasing factor related peptide) when encapsulated in Odorranalectin 
(bioadhesive from lectin family) functionalized PEG-PLGA nanoparticles in hemiparkinsonian rats  [91]. 
When administered intranasally, the Odorranalectin functionalized nanoparticles showed higher brain 
uptake and enhanced neuroprotection in experimental animals through direct pathway. Similarly, Migliore 
et al. (2014) reported the neurotropic and neuroprotective effect of GDNF following intranasal 
administration of GDNF loaded cationic liposomes (made up of dioleoylphosphatidylcholine (DOPC), 
cholesterol, and stearylamine) [92]. Intranasal GDNF protected the dopamine neurons within substantia 
nigra from acute 6-OHDP induced neuronal toxic insult [92]. Sharma et al. (2013) reported intranasal 
delivery of pluronic F-127 based thermoreversible gel containing levodopa encapsulated chitosan 
nanoparticles [93]. Chitosan being a muchoadhesive polymer plays an important role in improving drug 
absorption through nasal mucosa and can lead to opening of tight junctions across BBB. The in vivo findings 
revealed that intranasal administration showed maximum recovery of levodopa within the brain with 
chitosan nanoparticles [93]. Md and colleagues (2013) have studies the potential of intranasal route to 
enhance the brain delivery of bromocriptine (BRC) loaded chitosan nanoparticles in haloperidol induced PD 
mice [94]. When administered intranasally the BRC loaded nanoparticles showed pronounced reversion of 
catalepsy and akinesia induced by haloperidol. The biodistribution study revealed higher brain/blood ratio 
of BRC loaded nanoparticles following intranasal administration than that of intravenous route at 0.5 
hours, indicating direct nose to brain transport of BRC circumventing the BBB. The gamma scintigraphy 
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study revealed higher brain uptake and enhanced antioxidant potential of BRC following intranasal 
administration [94]. A flowchart of the various routes and approaches to cross the BBB has been outlined 
in Figure 4. 
 
 
Figure 4. Novel Approaches for drug delivery across the BBB (The approaches are mentioned within boxes. 
Those in red are invasive approaches and those in black are relatively less invasive approaches for drug 
delivery.) 
 
Passive Targeting (Macrophage loaded) 
Nanotechnology platforms possess the ability to accumulate in a specific organ without active targeting 
moieties on its surface due to certain inherent characteristics. For example, in cancers,  small size of 
nanoparticles allow them to preferentially accumulate at tumor sites by the Enhanced Permeation and 
Retention effect (EPR effect) which leverages the leakiness of blood vessels in a tumor and absence of 
lymphatics to deliver the nanoparticles [95]. In Parkinson’s disease, the BBB is an important barrier that 
needs to be crossed for the delivery of therapeutics. This can be achieved passively through macrophages. 
In PD there is a chemokine-gradient that gets induced through neuroinflammatory responses which allow 
concentration of macrophages in the brain as outlined in Figure 5. Hence, it is possible to use macrophages 
as drug carriers for the delivery of various therapeutic payloads [96]. Batrakova et al. delivered catalase 
using bone-marrow-derived macrophage (BMM) systems to PD-affected brain regions in an animal model 
[97]. The self-assembled catalase/polymer complexes referred to as nanozymes that were 60-100 nm in 
size were taken up by the BMMs and showed sustained release for about 24 hours as compared to 
immediate degradation of the free enzyme [97]. This had implications in decomposition of microglial 
hydrogen peroxide that could reduce oxidative stress in PD. It was found that the nanozymes loaded into 
BMMs increased deposition of labeled enzyme in tissues in vivo in MPTP-treated mice as compared to free 
enzymes. The development of such nanoparticles loaded into macrophages can help in increased delivery 
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of therapeutics to the brain reducing the need and the costs associated with active targeting of 
nanoparticles. 
 
Figure 5. Use of Nanotechnology for passive targeting through macrophages for drug delivery in Parkinson’s 
disease 
Stimulus responsive nanoparticles  
Nanoscale biomedical imaging for image guided therapy and diagnosis against neurodegenerative 
diseases is recently emerging. One of the widely studied multipurpose systems are magnetic nanoparticles 
(MNPs) with MRI contrast for applications like cellular and molecular imaging of various metastases, 
hyperthermia, drug delivery and tissue repair. In case of neurodegenerative diseases the presence of 
structural barrier likes BBB; restrict MNPs access to the CNS. Therefore smart engineering of MNPs with 
desired size and appropriate physicochemical properties is important to circumvent the BBB to gain access 
to the brain [70, 98]. Recently Qiao et al. (2012) developed target specific theranostics to facilitate the 
access of nanoparticles across BBB through endocytosis mediated by lactoferrin receptor. PEGylated 
magnetic nanoparticles (Fe3O4) surface modified with lactoferrin serve as a brain MRI guided delivery 
probe[99]. The in vitro porcine BBB model showed that amphiphilic PEG coating and lactoferrin conjugation 
facilitate the transport of MNPs across BBB [99]. The vascular imaging after intravenous injection of 
targeted MNPs confirm  lactoferrin receptor mediated transcytosis with  interaction between targeted 
nanoparticles and lactoferrin receptors expressed on microvascular endothelial cells [99]. Recently Hwang 
et al. (2009) reported ultrasound responsive stable perfluorocarbon nanobubbles (PNs) loaded with 
dopamine receptor agonist (apomorphine) for targeting the brain. The studies showed the improved 
stability and higher plasma residence time of apomorphine loaded PNs in vivo attributable to rigid 
cholesterol and phospholipid membrane. Ultrasound trigger altered the release profiles on demand. 
Erythrocyte hemolysis study demonstrated the safety profile (<10% hemolysis) of PNs [100]. Altogether 
these studies revealed the potential of stimulus sensitive nano-carriers for improving stability, 
administration frequency and on-demand release kinetics of therapeutics against PD. A brief 
representation of the use of nanobubbles as stimulus-responsive nanoparticles is provided in Figure 6. 
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Figure 6. Use of Stimulus responsive nanoparticles for drug delivery in Parkinson ’s disease with ultrasound 
(stimulus) responsive nanobubbles (nanoparticles) as an example 
Neuroprotection 
Neuroprotection is the ability for a treatment to prevent neuronal cell death by inhibition of the 
cascade resulting in cell dysfunction and eventually cell death. The relevance to PD lays in the fact that the 
pathogenesis of PD involves oxidative stress in substantia nigra through production of reactive oxygen 
species (ROS) and hydrogen peroxide by extensive oxidative metabolism of dopamine. Neurotrophic 
factors (like glial cell derived neurotrophic factor (GDNF)), fullerenes and nanoceria, show  neuroprotection 
in PD [101,102]. The response from direct infusion of GDNF to the putamen had initial success but later 
could not demonstrate any significant benefits in controlled clinical trials due to development of antibodies 
and cerebellar degeneration [103]. This called for better modes of controlled delivery of GDNF. Wang et al. 
described the use of microbubbles loaded with GDNF which released GDNF on low-frequency ultrasound 
stimulation in the treatment of PD-induced in rats [68]. GDNF levels  augmented in the striatum following 
low frequency ultrasound stimulation after the infusion of microbubbles and resulted in favorable 
biochemical and behavioral changes suggesting neuroprotective effects [68]. Thus, ultrasound responsive 
nanoparticles can be of use in the theranostics of PD- therapy by drug delivery and imaging due to the 
contrast provided by the microbubbles.  
In another approach, a number of non-viral gene delivery vectors are being developed that have 
reduced toxicities and have comparable efficiencies in transferring GDNF genes into the target cells. As has 
been mentioned earlier, lactoferrin-conjugated nanoparticles have been used successfully for this purpose  
in PD rat models [104]. Similarly, Angiopep with a sequence of TFFYGGSRGKRNNFKTEEYC as the targeting 
ligand to mediate BBB transport and cellular internalization was conjugated to poly-L-lysine-based 
dendrimer nanoparticles (dendrigraft poly-L-lysine) via hydrophilic polyethylene glycol (PEG) [105]. These 
nanoparticles constructs allowed effective gene expression both in vitro and in rat models of PD [105]. In 
addition to the delivery of neurotrophic factors, the use of fullerenes and nanoceria is of great interest. 
Pretreatment with polyhydroxylated fullerene derivative C(60)(OH)(24) at ≥20 µM concentrations were 
used by Cai et al. for the purposes of neuroprotection [106].  In an in vitro cellular model of Parkinson's 
disease, significant protective effects as reflected by cell viability, mitochondrial function; levels of reactive 
oxygen species decreased and DNA and proteins damage were reduced with polyhydroxylated fullerenes 
[106]. Also, fullerenes in the form of carboxyfullerenes (C3) showed neuroprotection in Macaque 
fascicularis monkeys [107]. The technology leveraging the antioxidant properties of fullerenes in the 
treatment of Parkinson's disease is being commercialized and the leading companies involved are The 
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Bronx Project, Inc. (TBP), Tego BioSciences Corporation (Tego) and  Luna Innovations Incorporated (Luna) 
[108]. In addition to this, cerium oxide (CeO2) is being used for its capability of neutralizing and reducing 
harmful reactive oxygen species in a redox reaction [102]. Due to the oxygen vacancies on the CeO2 surface 
and presence of both trivalent and tetravalent states of cerium ions, during the redox reaction the ions can 
flip-flop between the two oxidation states [102]. Leveraging this scavenging role of cerium oxide, Pinna et 
al.  showed a protective role of nanoceria both in vitro on PC12 cells survival and dopamine metabolism in 
manganese-induced Parkinson’s Disease [102].  
Other approaches in management of Parkinson’s Disease based on nanotechnology 
Neural prosthetic electrodes for Deep brain stimulation 
Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) through electrical stimulation 
using implanted neural prosthetic electrodes is a proven and FDA-approved treatment modality for 
advanced Parkinson's disease [109]. Deep brain stimulation has been found to be better than medical 
therapy in producing improvements in motor symptoms [109,110].  However, the precision of DBS is an 
important issue that needs to be tweaked to address the ethical implications of altering brain circuits with 
this technique [111]. For this purpose, neural stimulation has employed a wide range of metals and metal 
alloys as materials for fabrication of electrodes in neural stimulation. These include noble metals 
(Platinum), titanium oxide, activated iridium, tantalum oxide, and silicon [112]. However, these materials 
include limitations in the form of low charge injection limit allowing only large electrodes with low current 
density to be used [113], Faradaic reactions (consisting of electron transfer between electrode and 
electrolyte resulting in either reduction or oxidation of a particular chemical species in a given electrolyte) 
leading to diffusion of toxic products or the corrosion of electrodes [114] as well as issues with 
biocompatibility with the electrode materials [114].  
Carbon Nanotubes- One of the most versatile nanotechnology options explored for neural prosthetic 
electrodes are carbon nanotubes (CNTs) which have the unique combination of being strong (Young’s 
modulus more than 1 TPa) as well as flexible. Both of these are extremely important for fabrication of 
penetrating electrodes in neural prostheses [114]. Besides, to serve as an electrode for neural stimulation 
it should be able to deal with the critical trade-off between high charge injection limit and absence of 
Faradaic reactions. Wang et al. used multiwalled carbon nanotube (CNT) pillars to fabricate 
microelectrodes [112] and successfully created a neural interface prototype device using CNT microarrays 
containing CNT microelectrodes. The neurons could grow and differentiate on the interface as well as could 
be repeatedly excited. The important parameters that were identified included the high charge injection 
limit offered by these functionalized hydrophilic CNT microelectrodes without faradic reactions [114]. This 
ensured the efficient and safe electrical stimulation of neurons and had several uses in diagnosis and 
therapy of neurological diseases like PD [114]. 
Conducting Polymers- Another group of innovations in this field is the development of coatings on 
neural prosthetic implants using conductive polymers containing alternating double and single bonds in 
their structure [115]. Polypyrrole (PPy), poly(ethylene dioxythiophene) (PEDOT), polyaniline and 
polyterthiophene are  common examples of such  polymers [115].  George et al. found polypyrrole 
implants used in microfabricated neural prosthetics allowed the growth of neural connections on all 
surfaces [116]. However, these implants showed tissue reactions in the brain in the form of gliosis [116] 
which was  one of the major causes of failure of these electrode arrays within a few weeks after 
implantation [117]. To tackle this problem, Wadhwa et al. proposed PPy based coatings on the electrodes 
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with electrically controlled local delivery of dexamethasone (Dex), a drug which is known to reduce tissue 
reactions and gliosis [117]. Micromachining and one step electropolymerization was used for the 
deposition of a thin film (several nm) of PPy and the drug on the gold coated electrode surface for the 
fabrication of this smart electrode capable of responsiveness to electrical stimulus [117]. The added 
advantage of use of polypyrrole in such smart platforms is the fact that redox reactions cause the charging 
and discharging of these polymers and can lead to the movement of hydrated ions, drugs and growth 
factors in and out of the bulk of the polymer [117]. The drug loaded into the electrode was released in the 
buffer solution in the presence of an electrical trigger that was applied through cyclic voltammetry [117].  
Conductive polymer hydrogels- The increased biocompatibility of these drug-eluting coatings on smart 
microelectrodes led to research towards increasing the drug loading and stimulus responsiveness of the 
electrodes. This lead to conducting polymers  being incorporated inside hydrogel-support matrices, a class 
of materials called conductive polymer hydrogels (CPH) [118]. Such a matrix can allow more drug 
incorporation along with faster release [117]. These properties can be further enhanced through the 
increase in surface area by creating nano-fibrous morphology employing nano-templating techniques 
[117]. Such devices can serve as mechanical buffers in the interface between the hard electrodes and the 
soft brain tissue improving contact with viable neurons while increasing biocompatibility and limiting 
protein adsorption to the neural prosthetic electrodes [117,118]. According to a study by Nguyen et al., the 
incorporation of a mechanically-compliant implant in the brain parenchyma can reduce the inflammatory 
response in comparison to stiffer systems [119]. Thus, CPH coated electrodes are biocompatible by 
themselves and can be additionally used to deliver drugs and growth factors locally. . Kim et al. used PPy 
grown electrochemically on the scaffolds made of hydrogels followed by deposition on the surface of 
neural prosthetic devices [120]. The coating was found to reduce impedance and improve electrical 
properties of the electrodes [120]. However, hydrogels have the inherent property of a high swelling ratio 
and its swelling in situ can lead to increase in the distance from the brain surface and the microelectrode 
reducing the efficiency of deep brain stimulation. To deal with this problem, bio-inspired hybrid 
microelectrodes were fabricated by De Faveri et al. in which they used highly biocompatible fibrin coatings 
[121].  The fibrin coatings reduced host reaction within 7 days of implantation and allowed growth of both 
neurons and astrocytes [121]. But most importantly, the fibrin coating displayed a smaller swelling than 
other types of hydrogels and allowed the control of coating thickness [121]. Thus, the problem of hydrogel 
swelling could be tackled with suitable bio-inspired coatings. 
Thus, nanotechnology is being increasingly employed for the development of better neural prosthetic 
electrodes for deep brain stimulation. Further advances in the fabrication and stimulus responsiveness of 
these technologies can help incorporate DBS as a safer treatment modality in the management of 
Parkinson’s disease. 
Nanotechnology in neurosurgery 
After the introduction of levodopa half a century ago, neurosurgery was abandoned for the 
management of Parkinson’s disease. However, the past decade saw the resurgence of the surgical 
treatment of PD using pallidotomy and thalamotomy [103]. This was due to the inherent drawbacks of 
drug therapy in which the prolonged  administration of drugs lead to drug-induced motor symptoms [103]. 
With the advent of the age of nanotechnology, there have been great strides in the precision in 
neurosurgery.  
Laser Axotomy- One of the most intriguing techniques in the field of nanotechnology is the use of 
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femtosecond laser axotomy which is being developed as a neurosurgical tool with 100% efficiency, 
precision in the range of nanometers and high speed. The most widely cited example of this precise 
technique is by Yanik et al. (2011) where femtosecond laser axotomy was used to cut single axons inside 
the roundworm C. elegans by using focused nano-scale near-infrared laser pulse energies (10–40 
nanojoules) of 200-femtoseconds [122]. This resulted in the vaporization of femtolitres of axon volumes 
and subsequent cutting of the axon processes [122]. Besides, the technique was robust allowing the use of 
confocal fluorescence imaging and laser scanning brightfield for real-time imaging from the first incision to 
the end  [122].The surgical technique has improved understanding of a number of processes in nerve cell 
injury [123] and  has also paved way for an all new concept of nanomanipulation. 
Vibrating micropipette- Another widely popular technology is the use of a rapidly vibrating (100 Hz) 
micropipette (tip diameter in nanometers) which when dragged across the dendrite of a selected neuron  
can help in  dissection of apical dendrites  [124]. This provided  a simple system for cutting dendrites from 
single neurons without damaging the cell [124].  
Nanotweezers- The word nanotweezers is being widely used with different meanings but with the same 
purpose of precise manipulation in the nanometer range. The nanotweezers may be of nanoscale 
electromechanical systems based on carbon nanotubes fabricated on pulled glass micropipettes as 
described by Kim et al. [120]. Voltages that are applied to these electrodes could open or close the free 
ends of the nanotubes allowing grabbing and manipulation of submicron clusters and nanowires [120]. The 
mechanical capabilities of such nanotweezers can be put to use for grabbing and manipulating neurons as 
well. A rather higher level of precision in manipulation is by the use photoswitchable crosslinkers which in 
response to light can manipulate the normal physiological signal or induce structural changes in peptides 
and ion channels allowing molecular level manipulation of cells [125]. The use of light is being increasingly 
used for the study of disease circuitry in Parkinson’s disease especially through optogenetics which is a 
novel technique of gene delivery through encoding of proteins capable of instilling light sensitivity to 
neurons [126]. These technologies once translated can improve the precision of neurosurgery to molecular 
ranges. 
Nanotechnology and the use of smart nanoparticles can greatly improve the precision of such surgical 
devices from cutting neuronal processes to modifying ion channels using light. As these devices are 
gradually becoming popular in the lab, their translation to bedside is possible in the near future. The 
essential precision that these nanotechnological tools add, can lead to a safer neurosurgical option for 
patients with PD as with many other neurological diseases. 
Tissue Engineering Approaches - Finding the ideal platform 
The dopaminergic neurons in the substantia nigra responsible for cortical and thalamic regulation are 
lost in PD leading to motor dysfunction (tremor, rigidity, and bradykinesia) and non-motor symptoms 
(depression, anxiety) [103]. The transplantation of fetal tissue in the form of human fetal ventral 
mesencephalon was one of the most promising treatments in the 1980s and stimulated a number of 
clinical trials with varied protocols and endpoints [127,128]. There were reports of clinical improvement 
and two decades later, after sufficient evidence of safety and efficacy of these treatments, the National 
Institutes of Health, USA started two clinical trials in the early 2000s [127]. The trials found the therapy to 
be of little benefit to patients and caused some of the patients to become worse with symptoms like graft-
induced dyskinesias (GID) [127,129]. However, a decade later, the debate is still on regarding the efficiency 
of stem-cell grafting [128,129]. Besides the concerns in the clinical-trial design and ethical issues, the 
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technology needed to be safe [127,128].  These concerns are more pronounced with embryonic stem cells 
(ESCs) because of their ability to differentiate into a number of cell types [127]. A potential  solution is the 
use of patient derived cells and then induced pluripotent stem cells (iPSCs)  [127]. However, the concern 
still lies in the fact that the patient’s own cells may be susceptible to the PD pathology [127]. Thus, it is the 
trade-off between optimal ability to proliferate while dodging the pathogenesis of PD that forms the basis 
of development of a safe treatment for PD. Direct infusion of growth factors like glial cell–derived 
neurotrophic factor (GDNF) to the putamen in patients with PD has been found to be favorable and are 
being seen as prospective agents for neuroprotection [103]. However, these approaches are still to be 
verified as clinical trials reflect conflicting evidence [103]. Tissue engineering tries to address these issues 
using stem cells and growth factors in suitable scaffolds for the controlled regeneration of various tissues. 
It is being increasingly used for neural stem cell engineering for Parkinson’s disease.  
Nanoparticles for delivery of versatile payloads: One of the approaches in tissue engineering for PD is 
the use of small molecules as triggers to allow the differentiation of stem cells into the neurons. Santos et 
al. used retinoic acid-loaded polymeric nanoparticles to induce such differentiation in  subventricular zone 
neural stem cells [130]. The nanoparticles leveraged the electrostatic interaction of polyethylenimine 
(polycation) with retinoic acid and dextran sulfate (polyanion) [130]. The intracellular delivery of retinoic 
acid using nanoparticles increased the differentiation of stem cells into neurons as was confirmed using 
gene expression profiles. Such technologies can be of great use if nanoparticles containing retinoic acid are 
manufactured for targeting stem cell sequences to control in time and space the differentiation of stem 
cells [130].  
Scaffold design: In addition to using small molecules for the differentiation into a particular lineage, 
there can be changes made in the substrate too allowing nanoknitting of neurons on scaffolds [131]. Ni et 
al. developed a Self-Assembling Peptide Nanofiber Scaffold (SAPNS) 6–10 nm in diameter to enhance 
differentiation of ESCs as well as iPSCs into dopaminergic neurons in a 3-dimensional culture [132]. This 
was confirmed using gene expression, maturation, immunocytochemistry and dopamine release all of 
which proved genetically and functionally differentiated dopaminergic neurons in the scaffold [132]. 
Hence, these materials have the potential to be used for neuroprostheses. In addition to this, materials 
used in neural prosthetic electrodes have also been used in tissue engineering. Conductive polymer 
hydrogels (CPH) have the advantage of allowing cell immobilization while increasing the surface area and 
electrical properties necessary for nerve growth and regeneration [117,118,120]. 
Thus, nanotechnology-based platforms are increasingly being used to tackle the challenges of stem-cell 
delivery. The present day platforms based on nanotechnology would allow a more precise and accurate 
delivery of stem cells for the management of Parkinson’s disease. A brief summary of the use of 
nanotechnology in these therapies is represented in Figure 7. 
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Figure 7. Nanotechnology-based platforms for the management of Parkinson’s disease 
Translation, Future Prospects and Concerns  
The increased awareness of PD and the accelerated research towards its management has lead to the 
infusion of a number of technologies into the scenario. Nanotechnology is a novel and versatile addition to 
the fight against PD. There have been efforts in accelerating research in the identification of novel 
biomarkers and strategies for the cure for PD. This has led to a lot of research reach from labs to the 
bedside. Nanotechnology has the ability to develop smarter sensors for the diagnosis of PD using these 
novel biomarkers and imaging modalities. It is also being used for the targeted treatment of PD, in 
neuroprotection and in stem cell therapies. 
Multinational technology companies are also entering the arena of nanotechnology to treat Parkinson’s 
disease. Google Inc. has recently filed a patent for a wearable device in the form of a watch or bracelet that 
can direct functionalized nanoparticles (like magnetic nanoparticles through the magnetic field generated 
by the device) into the subsurface vasculature present close to the device [133]. The patent claims  that 
there is a potential for the use of such devices in the treatment of PD by targeting certain proteins [133]. 
Besides, the clinical translation of research has lead to the development of a number of commercial 
entities. The Bronx Project, Inc. (TBP), Tego BioSciences Corporation (Tego) and  Luna Innovations 
Incorporated (Luna) [108] are involved in the development of fullerenes for neuroprotection in PD. 
Parkinson’s Pen (by Manus Neurodynamica Ltd.) is another patented technology that uses the changes in 
handwriting in  combination with  a sensor device on the pen to analyze the force exerted by each of the 
fingers,  and the changes in handwriting [73]. Such pressure sensors and detectors can be of  use to detect 
PD. Parkinson’s Pen itself in its initial testing was able to distinguish 10 people with PD from age- and sex-
matched controls with 90% sensitivity and 80 % specificity [134]. A clinical trial with a larger sample size is 
underway to confirm the sensitivity and specificity of the promising device [134]. This technology will have 
applications in diagnostics, pre-symptomatic screening, disease monitoring, treatment response and 
rehabilitation. The company is currently conducting clinical trials to this end. Thus, there is a lot of 
translation that is taking place from diagnosis to rehabilitation of PD patients.  
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Another area that is developing a lot in PD is the use of stem cells. Nanotechnology affords a targeted 
and controlled delivery and differentiation of stem cells for the therapy of PD. However, one of the biggest 
concerns in the present day is the development of treatments of PD using unproven cell-based treatments 
which pose serious threats to research  translation [128]. These therapies pose increased risk of tumor 
formation [126]. Such therapies continue to be performed without intensive testing in vitro and in vivo and 
pose a serious risk to jeopardize the spark of hope that is gradually infused in the sphere due to the advent 
of tissue engineering and nanotechnology [128].  
In addition to this, there are ethical concerns raised regarding neurology and nanotechnology and their 
potential impact for which there is a need for a multidisciplinary bioethical enquiry [135]. Also, there are 
conflicting reports regarding toxicity of certain nanoparticles which cross the blood brain barrier [136-138]. 
This has called for further evaluation of nanoparticles for surface properties, size and constituents for 
finetuning the therapeutic effects while avoiding toxic effects [136]. For drug delivery formulations, it is 
imperative to increase the therapeutic window which is the range of dosage that can effectively treat 
disease while staying in the safety range and without inducing adverse effects [136]. Comprehensive 
testing for efficacy and toxicity must be performed before the introduction of nanotechnology-based 
systems into the market [136]. According to the Royal Society/Royal Academy of Engineering report 
(2004), carbon nanotubes should be comprehensively tested as “new substances” for their potential 
toxicities under UK and European Health, Safety and Environment legislation before they are introduced in 
the market [57]. However, each nanoparticle is unique and it is necessary to understand the specific issues 
associated with each type of nanoparticle for evaluation of toxicity issues. Use of green chemistry, 
degradable materials, and regulatory approvals for nanotechnology-based products are the positive signals 
towards an optimistic future with nanotechnology, the effects of which can be of potential benefit to 
patients with PD. 
Conclusions 
Parkinson’s disease has a huge impact on the lives of the patients with tremendous socioeconomic 
effects. Nanotechnology can serve as a viable alternative to the present day diagnosis and treatment of PD 
by providing novel, affordable and accessible devices. Nanotechnological platforms are being increasingly 
developed with applications in the management of PD. The optimism in the translation of these 
technologies from labs to bedside can be seen with increasing interest by grant agencies, companies and 
physicians towards their development. The tremendous potential to tweak nanoparticles in the nanoscale 
can prove to be of great help in the fight against Parkinson’s disease. 
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